@article{TCR8956,
author = {Claus Jørgensen and Elizabeth K. J. Hogg},
title = {CRISPR/Cas9 engineering offers new opportunities to model pancreatic ductal adenocarcinoma development},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 2},
year = {2016},
keywords = {},
abstract = {Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease. The 5-year survival is below 5%, which is due to a combination of aggressive disease progression, late diagnosis and limited treatment options (1). Consequently, PDAC is predicted to be the second-largest contributor to cancer related deaths by 2020 (2). New approaches and models to accelerate therapeutic development and improve patient outcome are therefore urgently needed.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/8956}
}